MX2021005992A - Gaboxadol para reducir el riesgo de suicidio y para alivio rápido de la depresión. - Google Patents
Gaboxadol para reducir el riesgo de suicidio y para alivio rápido de la depresión.Info
- Publication number
- MX2021005992A MX2021005992A MX2021005992A MX2021005992A MX2021005992A MX 2021005992 A MX2021005992 A MX 2021005992A MX 2021005992 A MX2021005992 A MX 2021005992A MX 2021005992 A MX2021005992 A MX 2021005992A MX 2021005992 A MX2021005992 A MX 2021005992A
- Authority
- MX
- Mexico
- Prior art keywords
- depression
- gaboxadol
- suicide
- reducing risk
- rapid relief
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862770287P | 2018-11-21 | 2018-11-21 | |
| PCT/US2019/062554 WO2020106927A1 (en) | 2018-11-21 | 2019-11-21 | Gaboxadol for reducing risk of suicide and rapid relief of depression |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2021005992A true MX2021005992A (es) | 2021-09-14 |
Family
ID=70728606
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2021005992A MX2021005992A (es) | 2018-11-21 | 2019-11-21 | Gaboxadol para reducir el riesgo de suicidio y para alivio rápido de la depresión. |
Country Status (13)
| Country | Link |
|---|---|
| US (3) | US20220008398A1 (zh) |
| EP (1) | EP3883566A4 (zh) |
| JP (1) | JP2022514194A (zh) |
| KR (1) | KR20210110585A (zh) |
| CN (1) | CN113395962A (zh) |
| AU (1) | AU2019384157A1 (zh) |
| BR (1) | BR112021009944A2 (zh) |
| CA (1) | CA3120856A1 (zh) |
| GB (1) | GB2594616A (zh) |
| IL (1) | IL283311A (zh) |
| MX (1) | MX2021005992A (zh) |
| SG (1) | SG11202105358RA (zh) |
| WO (1) | WO2020106927A1 (zh) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2015002252A (es) | 2012-08-21 | 2015-07-21 | Sage Therapeutics Inc | Metodos para tratar epilepsia o estado de epilepsia. |
| JOP20200195A1 (ar) | 2014-09-08 | 2017-06-16 | Sage Therapeutics Inc | سترويدات وتركيبات نشطة عصبياً، واستخداماتها |
| IL300422A (en) | 2016-03-08 | 2023-04-01 | Sage Therapeutics Inc | Neuroactive steroids, preparations and their uses |
| WO2018031748A1 (en) * | 2016-08-11 | 2018-02-15 | Ovid Therapeutics Inc. | Methods and compositions for treatment of epileptic disorders |
| US10071083B2 (en) * | 2017-02-03 | 2018-09-11 | Ovid Therapeutics Inc | Use of gaboxadol in the treatment of tinnitus |
| US20220008398A1 (en) * | 2018-11-21 | 2022-01-13 | Certego Therapeutics | Gaboxadol for reducing risk of suicide and rapid relief of depression |
| KR20230028244A (ko) | 2020-05-20 | 2023-02-28 | 썰테고 테라퓨틱스 아이엔씨. | 고리 중수소화 가복사돌 및 정신 장애의 치료를 위한 이의 용도 |
Family Cites Families (60)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK270278A (da) | 1977-06-20 | 1978-12-21 | Krogsgaard Larsen P | Cycliske aminosyrer |
| US4362731A (en) | 1980-09-01 | 1982-12-07 | Sandoz Ltd. | Myotonolytic use of 4,5,6,7-tetrahydroisoxazolo [5,4-c] pyridin-3-ol and derivatives thereof |
| US4353910A (en) | 1981-11-27 | 1982-10-12 | Kefalas A/S | Derivatives of 4,5,6,7-tetrahydroisoxazolo [5,4-c] pyridine-3-one, pharmaceutical compositions and methods of treatment |
| DE19525598C2 (de) | 1995-07-13 | 1997-09-25 | Max Planck Gesellschaft | Schlafmittel |
| AR031473A1 (es) | 2000-11-20 | 2003-09-24 | Lundbeck & Co As H | Intensificadores de gaba en el tratamiento de enfermedades relacionadas con una reducida actividad neuroesteroide |
| US20020165217A1 (en) | 2001-05-01 | 2002-11-07 | Pfizer Inc. | Combination treatment for anxiety and depression |
| ATE459353T1 (de) | 2003-06-25 | 2010-03-15 | Lundbeck & Co As H | Gaboxadol zur behandlung von depressionen und anderen affektiven störungen |
| TW200501951A (en) | 2003-06-25 | 2005-01-16 | Lundbeck & Co As H | Treatment of neuropathic pain, fibromyalgia or rheumatoid arthritis |
| US20050234093A1 (en) | 2003-06-25 | 2005-10-20 | H. Lundbeck A/S | Treatment of depression and other affective disorders |
| TW200509918A (en) | 2003-06-25 | 2005-03-16 | Lundbeck & Co As H | Treatment of depression and other affective disorders |
| CL2004001603A1 (es) * | 2003-06-25 | 2005-05-27 | Lundbeck & Co As H | Uso de gabaxadol para preparar un medicamento util para el tratamiento del dolor neuropatico. |
| AR045540A1 (es) | 2003-09-05 | 2005-11-02 | Lundbeck & Co As H | Metodo de elaboracion de 4,5,6,7 tetrahidroisoxazol [5,4-c] piridin-3-ol (thip) |
| UY28650A1 (es) * | 2003-12-05 | 2005-02-28 | Forest Laboratories | Memantina para la prevencion o disminucion de la conducta suicida y para el tratamiento de la depresion mayor asociada con esta conducta |
| US20050137222A1 (en) | 2003-12-18 | 2005-06-23 | H. Lundbeck A/S | Treatment of insomnia in human patients |
| GB0402118D0 (en) | 2004-01-30 | 2004-03-03 | Merck Sharp & Dohme | Polymorphic forms of a GABAA agonist |
| EA200601853A1 (ru) | 2004-04-02 | 2007-02-27 | Х. Лундбекк А/С | Лечение нарушенной дыхательной функции |
| MXPA06011325A (es) | 2004-04-02 | 2006-12-15 | Lundbeck & Co As H | Tratamiento de la funcion respiratoria alterada con gaboxadol. |
| GB0417558D0 (en) | 2004-08-06 | 2004-09-08 | Merck Sharp & Dohme | Novel combination therapy |
| EP2292222A1 (en) | 2005-01-28 | 2011-03-09 | H. Lundbeck A/S | Polymorphic Forms of a GABAA Agonist |
| EP1906953A4 (en) | 2005-04-29 | 2009-05-20 | Lundbeck & Co As H | FORMS OF ACID SALTS AND BASIC SALTS OF GABOXADOL |
| DE102005020882A1 (de) | 2005-05-04 | 2006-11-09 | Dömling, Alexander, Dr. | Verwendung von Gaboxadol und Derivaten zur Behandlung von Kinase-induzierten Krankheiten |
| FR2889811B1 (fr) | 2005-08-19 | 2009-10-09 | Sanofi Aventis Sa | Association d'un agent hypnotique a duree d'action longue et d'un agent hypnotique a duree d'action courte, composition pharmaceutique la contenant et son application en therapeutique. |
| US8785500B2 (en) * | 2006-03-22 | 2014-07-22 | Icahn School Of Medicine At Mount Sinai | Intranasal administration of ketamine to treat depression |
| US20080159958A1 (en) | 2006-12-27 | 2008-07-03 | Abbott Laboratories | Determination of histamine-3 bioactivity |
| US20090048288A1 (en) | 2007-08-13 | 2009-02-19 | H. Lundbeck A/S | Method of treating stress-mediated depression |
| TW200920358A (en) | 2007-08-13 | 2009-05-16 | Lundbeck & Co As H | Method of treating stress-mediated depression |
| US20090143335A1 (en) | 2007-10-29 | 2009-06-04 | H. Lundbeck A/S | Modified absorption formulation of gaboxadol |
| GB0810063D0 (en) | 2008-06-03 | 2008-07-09 | Renovo Ltd | Medicaments and methods for inhibition of scarring |
| JP2012501301A (ja) | 2008-09-01 | 2012-01-19 | ハー・ルンドベック・アクチエゼルスカベット | ガボキサドールおよびｐａｔ１阻害薬またはｏａｔ阻害薬を含む医薬組成物 |
| WO2015153658A2 (en) * | 2014-03-31 | 2015-10-08 | University Of Maryland, Baltimore | Use of negative modulators of gaba receptors containing alpha5 subunits as fast acting antidepressants |
| US20150313903A1 (en) | 2014-05-05 | 2015-11-05 | Ovid Therapeutics Inc. | Methods of treating cognitive impairment associated with neurodegenerative disorders |
| MX2020012404A (es) | 2014-06-06 | 2022-04-11 | Ovid Therapeutics Inc | Metodos para incrementar la inhibicion tonica y para tratar insomnio secundario. |
| US20170304358A1 (en) | 2014-10-06 | 2017-10-26 | Seyyed Nassir GHAEMI | Primary and secondary prevention of dementias and suicide with trace dose lithium |
| JP6735284B2 (ja) | 2015-03-24 | 2020-08-05 | ハー・ルンドベック・アクチエゼルスカベット | ４，５，６，７−テトラヒドロイソオキサゾロ［５，４−ｃ］ピリジン−３−オールの製造 |
| WO2016176609A1 (en) | 2015-04-30 | 2016-11-03 | Ovid Therapeutics Inc | Methods of treating prader-willi syndrome |
| US9682069B2 (en) | 2015-07-17 | 2017-06-20 | Ovid Therapeutics Inc | Methods of treating Dravet syndrome |
| PE20190338A1 (es) | 2015-07-17 | 2019-03-07 | Ovid Therapeutics Inc | Metodos de tratamiento de trastornos del desarrollo con gaboxadol |
| US20170348232A1 (en) | 2016-06-07 | 2017-12-07 | Ovid Therapeutics Inc. | Formulations of gaboxadol for treatment of angelman syndrome, fragile x syndrome and fragile x-associated tremor/ataxia syndrome |
| AR105378A1 (es) | 2015-07-17 | 2017-09-27 | Ovid Therapeutics Inc | Métodos de tratamiento de trastornos del desarrollo con gaboxadol |
| US9399034B1 (en) | 2015-08-11 | 2016-07-26 | Ovid Therapeutics Inc | Methods of sedation during critical care treatment |
| WO2017027249A1 (en) * | 2015-08-11 | 2017-02-16 | Ovid Therapeutics Inc. | Methods of sedation and parenteral formulation for use during critical care treatment |
| CA2994952A1 (en) | 2015-08-11 | 2017-02-16 | Ovid Therapeutics Inc. | Methods of sedation and parenteral formulation for use during critical care treatment |
| AR105670A1 (es) | 2015-08-11 | 2017-10-25 | Ovid Therapeutics Inc | Métodos de sedación parenteral para usar durante el tratamiento de cuidados intensivos |
| US9351968B1 (en) | 2015-09-09 | 2016-05-31 | Ovid Therapeutics Inc | Methods of treating developmental disorders using pipradrol |
| WO2017066421A1 (en) | 2015-10-13 | 2017-04-20 | Ovid Therapeutics Inc. | Treatment of cognitive impairment |
| KR20190013737A (ko) | 2016-05-26 | 2019-02-11 | 오비드 테라퓨틱스 인크. | 피프라드롤을 이용한 행동 증후군들의 치료 방법들 |
| WO2018031748A1 (en) | 2016-08-11 | 2018-02-15 | Ovid Therapeutics Inc. | Methods and compositions for treatment of epileptic disorders |
| CA3043626A1 (en) | 2016-11-22 | 2018-05-31 | Ovid Therapeutics Inc. | Methods of treating attention deficit/hyperactivity disorder with gaboxadol |
| US11535568B2 (en) | 2016-11-30 | 2022-12-27 | Hrl Laboratories, Llc | Monomer formulations and methods for 3D printing of preceramic polymers |
| US10071083B2 (en) | 2017-02-03 | 2018-09-11 | Ovid Therapeutics Inc | Use of gaboxadol in the treatment of tinnitus |
| JP2020511473A (ja) | 2017-03-15 | 2020-04-16 | オービッド・セラピューティクス・インコーポレイテッドＯｖｉｄ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｉｎｃ． | 発作性疾患の治療におけるデザイナー化合物によりのみ活性化するデザイナー受容体の使用 |
| US20180338959A1 (en) | 2017-05-24 | 2018-11-29 | Ovid Therapeutics Inc. | Treatment of depressive disorders |
| US20180344745A1 (en) | 2017-06-01 | 2018-12-06 | Ovid Therapeutics Inc. | Treatment of developmental disorders with imidazolone derivatives |
| US20190000993A1 (en) | 2017-06-28 | 2019-01-03 | Ovid Therapeutics Inc. | Treatment of developmental syndromes |
| EP3648762A4 (en) | 2017-08-04 | 2021-03-24 | Ovid Therapeutics, Inc. | USE OF GABOXADOL IN THE TREATMENT OF DIABETES AND RELATED DISEASES |
| CN111163811A (zh) | 2017-08-25 | 2020-05-15 | 奥维德医疗公司 | 重组腺相关载体 |
| KR20200053570A (ko) | 2017-09-12 | 2020-05-18 | 오비드 테라퓨틱스 인크. | 기면증의 치료에서 가복사돌의 사용 |
| CN107595850A (zh) | 2017-10-25 | 2018-01-19 | 桂林浩新科技服务有限公司 | 一种有效提高睡眠质量的药物组合物及其用途 |
| KR20210039324A (ko) | 2018-04-06 | 2021-04-09 | 오비드 테라퓨틱스 인크. | 물질 사용 장애들의 치료에서 가복사돌의 사용 |
| US20220008398A1 (en) * | 2018-11-21 | 2022-01-13 | Certego Therapeutics | Gaboxadol for reducing risk of suicide and rapid relief of depression |
-
2019
- 2019-11-21 US US17/295,845 patent/US20220008398A1/en not_active Abandoned
- 2019-11-21 US US16/691,049 patent/US11123332B2/en active Active
- 2019-11-21 EP EP19886329.2A patent/EP3883566A4/en active Pending
- 2019-11-21 MX MX2021005992A patent/MX2021005992A/es unknown
- 2019-11-21 WO PCT/US2019/062554 patent/WO2020106927A1/en unknown
- 2019-11-21 AU AU2019384157A patent/AU2019384157A1/en active Pending
- 2019-11-21 BR BR112021009944-1A patent/BR112021009944A2/pt unknown
- 2019-11-21 CA CA3120856A patent/CA3120856A1/en active Pending
- 2019-11-21 GB GB2108720.0A patent/GB2594616A/en not_active Withdrawn
- 2019-11-21 KR KR1020217019089A patent/KR20210110585A/ko unknown
- 2019-11-21 CN CN201980089656.6A patent/CN113395962A/zh active Pending
- 2019-11-21 JP JP2021529111A patent/JP2022514194A/ja active Pending
- 2019-11-21 SG SG11202105358RA patent/SG11202105358RA/en unknown
-
2021
- 2021-04-02 US US17/221,178 patent/US20220054461A1/en active Pending
- 2021-05-20 IL IL283311A patent/IL283311A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2020106927A1 (en) | 2020-05-28 |
| US20220054461A1 (en) | 2022-02-24 |
| CA3120856A1 (en) | 2020-05-28 |
| US20220008398A1 (en) | 2022-01-13 |
| JP2022514194A (ja) | 2022-02-10 |
| CN113395962A (zh) | 2021-09-14 |
| SG11202105358RA (en) | 2021-06-29 |
| US11123332B2 (en) | 2021-09-21 |
| EP3883566A4 (en) | 2022-09-07 |
| EP3883566A1 (en) | 2021-09-29 |
| BR112021009944A2 (pt) | 2021-08-17 |
| GB202108720D0 (en) | 2021-08-04 |
| KR20210110585A (ko) | 2021-09-08 |
| US20200155522A1 (en) | 2020-05-21 |
| IL283311A (en) | 2021-07-29 |
| AU2019384157A1 (en) | 2021-06-17 |
| GB2594616A (en) | 2021-11-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2021005992A (es) | Gaboxadol para reducir el riesgo de suicidio y para alivio rápido de la depresión. | |
| MX2021004639A (es) | Combinaciones de inhibidores de desmetilasa-1 especifica de lisina (lsd1) para uso en el tratamiento de tumores solidos. | |
| MX2020009773A (es) | Terapia de combinacion. | |
| MX2018001435A (es) | Metodos de tratamiento del sindrome de lennox-gastaut con fenfluramina. | |
| MX2019013279A (es) | Metodos de tratamiento del sindrome de doose utilizando fenfluramina. | |
| PH12019500845A1 (en) | Combinations comprising an ssao/vap-1 inhibitor and a sglt2 inhibitor, uses thereof | |
| EP4324521A3 (en) | Treatment of fabry disease in ert-naive and ert-experienced patients | |
| MX2009008582A (es) | Metodo para la administracion terapeutica de dihidroergotamina para permitir un rapido alivio de la migraña mientras se minimiza el perfil de efectos secundarios. | |
| MX2024010140A (es) | Nuevos metodos. | |
| RU2017134443A (ru) | Способ лечения с применением традипитанта | |
| PH12018502422A1 (en) | Nanoliposomal irinotecan for use in treating small cell lung cancer | |
| MX2019003134A (es) | Terapia de combinacion. | |
| MX2020011295A (es) | Tratamiento de dermatitis atopica. | |
| MX2020001727A (es) | Terapia de combinacion. | |
| AU2018282104A1 (en) | Use of vibegron to treat overactive bladder | |
| MX2022003190A (es) | Terapias de combinacion para el tratamiento de cancer que comprenden un derivado de bacterioclorofila. | |
| MX2023001425A (es) | Inhibidores de cinasa de insercion proviral en linfomas murinos (pim) para el tratamiento de neoplasias mieloproliferativas y fibrosis asociadas con cancer. | |
| MX2016008027A (es) | Uso de laquinimod para retrasar la evolucion de la enfermedad de huntington. | |
| MX2022014792A (es) | Cocristales, composiciones farmaceuticas de los mismos y metodos de tratamiento que los implican. | |
| MX2021014523A (es) | Metodos para tratar colangiocarcinoma. | |
| MX2022000394A (es) | Combinaciones terapeuticas de paclitaxel oralmente administrado y un inhibidor de la bomba de p-glicoproteina (p-gp) para el tratamiento del cancer. | |
| MX2020008881A (es) | Métodos de tratamiento contra el cáncer que comprenden inhibidores de chk1. | |
| MX2023007826A (es) | Metodos que comprenden una dosificacion intermitente fija de cediranib. | |
| EA202191165A1 (ru) | Элацестрант в комбинации с абемациклибом у женщин с раком молочной железы | |
| MX2023015097A (es) | Tratamiento de sintomas asociados a neoplasias mieloproliferativas. |